ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 327 for:    "Eye Diseases, Hereditary" OR "Peters plus syndrome"

Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa (PIONEER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03326336
Recruitment Status : Not yet recruiting
First Posted : October 31, 2017
Last Update Posted : April 6, 2018
Sponsor:
Information provided by (Responsible Party):
GenSight Biologics

Brief Summary:
The objective of this study is to evaluate the safety and tolerability of escalating doses of a gene therapy called GS030-DP (injected study treatment) administered via a single intravitreal injection and repeated light stimulation using a medical device called GS030-MD (stimulating glasses) in subjects with documented diagnosis of non-syndromic Retinitis Pigmentosa

Condition or disease Intervention/treatment Phase
Non-syndromic Retinitis Pigmentosa Combination Product: Gene therapy: GS030-DP AND Medical device: GS030-MD Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Intervention Model: Sequential Assignment
Intervention Model Description: 3 dose-escalation cohorts with 3 subjects per each cohort plus 1 extension cohort at the highest well-tolerated dose.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
Estimated Study Start Date : May 2018
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : May 2024


Arm Intervention/treatment
Cohort
3 dose escalation cohorts (low, medium and high dose) with 3 subjects per cohort followed by an extension cohort at the highest-well tolerated dose with 3 to 9 subjects.
Combination Product: Gene therapy: GS030-DP AND Medical device: GS030-MD
GS030-Drug Product (GS030-DP) - Recombinant adeno-associated viral vector, derived from serotype 2 (rAAV2.7m8), containing the optimized channelrhodopsin ChrimsonR-tdTomato gene under the control of the ubiquitous CAG promoter (rAAV2.7m8-CAG-ChrimsonR-tdTomato) GS030-Medical Device (GS030-MD) - Visual Interface Stimulating Glasses (that amplify the external visual stimulus to the optogenetically engineered retina)




Primary Outcome Measures :
  1. The safety and tolerability of escalating doses of GS030-DP administered via a single IVT and repeated light stimulation using GS030-MD in subjects with non-syndromic Retinitis Pigmentosa [ Time Frame: Week 52/Year 1 ]
    Safety and tolerability of GS030 treatment at Week 52/Year 1, by assessments based on local and systemic safety issues, specifically those related to IVT of GS030-DP and the subsequent repeated use of GS030-MD, as assessed by incidence of Adverse Events.


Secondary Outcome Measures :
  1. Evaluate the treatment effect of GS030 as assessed by visual acuity [ Time Frame: Week 52/Year 1 ]
    Assessment of the treatment effect with the change from baseline to Week 52 of parameters measured with the Freiburg Visual Acuity & Contrast Test (FrACT) free computer program that uses graphics capabilities and psychometric methods to provide automated, self-paced measurement and the full field threshold stimulus test (FST) measuring the illuminance necessary to stimulate the most sensitive parts of the retina, and thus determines a quantifiable stimulation threshold (before and after gene transfer, with GS030-MD turned ON and turned OFF).

  2. Evaluate the treatment effect of GS030 as assessed by visual function [ Time Frame: Week 52/Year 1 ]
    Assessment of the treatment effect with the change from baseline to Week 52 of parameters measured with Humphrey visual field 10-2 Standardized automated perimetry, square localization test, displaying white square at a random location on a black background and direction of motion test measuring the ability of subjects to determine the direction of an object moving in the visual field (before and after gene transfer, with GS030-MD turned ON and turned OFF).

  3. Evaluate the treatment effect of GS030 as assessed by mobility. [ Time Frame: Week 52/Year 1 ]
    Assessment of the treatment effect with the change from baseline to Week 52 of parameters measured with door task (before and after gene transfer, with GS030-MD turned ON and turned OFF).

  4. Evaluate the treatment effect of GS030 as assessed by mobility. [ Time Frame: Week 52/Year 1 ]
    Assessment of the treatment effect with the change from baseline to Week 52 of parameters measured with line task (before and after gene transfer, with GS030-MD turned ON and turned OFF).

  5. Evaluate the treatment effect of GS030 as assessed by QoL [ Time Frame: Week 52/Year 1 ]
    Assessment of the treatment effect on quality of life changes from baseline to Week 52 with the Visual Functioning Questionnaire-25 (VFQ-25). VFQ25 is a 25-item questionnaire with 47 questions, each question has several responses scored on a scale from 0 to 5, 0 to 6, or 0 to 10. Values are calculated in percentages.

  6. Evaluate the treatment effect of GS030 as assessed by QoL [ Time Frame: Week 52/Year 1 ]
    Assessment of the treatment effect on quality of life changes from baseline to Week 52 with the Short Form Survey 36 Version 2 (SF-36v2). The SF-36v2 is a subject-rated 36-item questionnaire assessing subject health. There are 8 scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0 to 100 scale. A lower score indicates more disability, and a higher score indicates less disability (a score of 0 is equivalent to maximum disability, and a score of 100 is equivalent to no disability).

  7. Evaluate immune response to recombinant adeno associated viral vector, derived from serotype 2 (rAAV2.7m8) and ChR tdT protein. [ Time Frame: Week 52/Year 1 ]
    Immune response to rAAV2.7m8 and ChR-tdT protein from baseline to week 52



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main selection criteria:

  • Age ≥18 years to ≤75 years at the time of ICF signature.
  • Diagnosis of non-syndromic RP defined as:

    • Clinical diagnosis of non-syndromic RP based on history, mid-peripheral visual dysfunction, and fundoscopic appearance.
    • Diagnosis of non-syndromic RP is confirmed on full-field ERG
  • Visual acuity:

    • Visual acuity in the dose-escalation cohorts of no better LP.
    • Visual acuity in the extension cohort of no better than CF pending review of dose-escalation cohort data by the DSMB.
  • Interpupillary distance of ≥51 mm and ≤72 mm.
  • Refractive error of the study eye between -6 diopters and +6 diopters.

Main non-selection criteria

  • Prior receipt of any gene therapy.
  • Subjects who have undergone significant ocular surgery (per investigator determination) within 3 months prior to Visit 1.
  • Presence of narrow iridocorneal angles contraindicating pupillary dilation.
  • Presence of disorders of the ocular media which interfere with visual acuity and other ocular assessments, including SD-OCT, during the study period.
  • Presence of any systemic or ocular diseases, or pathologies, other than non-syndromic RP, or their associated therapies, that can cause or have the potential to cause vision loss.
  • Prior vitrectomy or vitreomacular surgery.
  • Presence of vitreo-macular adhesion or traction, epiretinal membrane, macular pucker and macular hole, evident by ophthalmoscopy and/or by SD-OCT examinations and assessed by the investigator to significantly affect central vision.
  • Current evidence of retinal detachment assessed by the investigator to significantly affect central vision.
  • Active ocular inflammation or recurrent history of idiopathic or autoimmune associated uveitis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03326336


Contacts
Contact: Barrett Katz, MD +1 646 831 3799 bkatz@GENSIGHT-BIOLOGICS.COM
Contact: Serge Fitoussi, MD +33 (0)6 65 75 78 41 sfitoussi@gensight-biologics.com

Sponsors and Collaborators
GenSight Biologics

Additional Information:
Responsible Party: GenSight Biologics
ClinicalTrials.gov Identifier: NCT03326336     History of Changes
Other Study ID Numbers: GS030_CLIN_001
2017-002204-27 ( EudraCT Number )
First Posted: October 31, 2017    Key Record Dates
Last Update Posted: April 6, 2018
Last Verified: October 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by GenSight Biologics:
Hereditary Eye Diseases
Eye Diseases
Retinal degeneration
Inherited retinal diseases
Rod & cone dystrophies
Retinitis Pigmentosa
Gene Therapy
Optogenetic
Intravitreal Injections
AAV Vectors
Medical device
Visual Interface

Additional relevant MeSH terms:
Retinitis
Retinitis Pigmentosa
Cone-Rod Dystrophies
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Dystrophies
Retinal Degeneration
Genetic Diseases, Inborn